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During a 17-month period, we performed retrospective analyses of the prevalence of and clinical symptoms
associated with human metapneumovirus (hMPV) infection, among patients in a university hospital in The
Netherlands. All available nasal-aspirate, throat-swab, sputum, and bronchoalveolar-lavage samples (Np
) were tested for hMPV RNA by reverse-transcriptase polymerase chain reaction. hMPV RNA was detected1515
in 7% of samples from patients with respiratory tract illnesses (RTIs) and was the second-most-detected viral
pathogen in these patients during the last 2 winter seasons. hMPV was detected primarily in very young
children and in immunocompromised individuals. In young children, clinical symptoms associated with hMPV
infection were similar to those associated with human respiratory syncytial virus (hRSV) infection, but dyspnea,
feeding difficulties, and hypoxemia were reported more frequently in hRSV-infected children. Treatment with
antibiotics and corticosteroids was reported more frequently in hMPV-infected children. From these data, we
conclude that hMPV is an important pathogen associated with RTI.
Acute respiratory tract illnesses (RTIs) are the most
common diseases experienced by people of all ages
worldwide [1]. In young children, human respiratory
syncytial virus (hRSV) is the most common cause of
RTI [1–3]. Recently, a previously unknown pneumo-
virus was isolated from nasopharyngeal-aspirate sam-
ples obtained from children with RTIs in The Neth-
erlands [4]. Those preliminary data indicated that the
clinical symptoms of the children were similar to those
of patients with RTI caused by hRSV, ranging from mild
respiratory problems to severe cough, bronchiolitis, and
pneumonia, often accompanied by high fever, myalgia,
and vomiting. Some of those patients were hospitalized
and required mechanical ventilation. On the basis of
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the organization of the viral genome and sequence iden-
tity to the Metapneumovirus avian pneumovirus, also
known as turkey rhinotracheitis virus [5, 6], the virus
was named human metapneumovirus (hMPV) [4, 7].
As a result, the Pneumovirus and Metapneumovirus gen-
era within the subfamily Pneumovirinae (family Para-
myxoviridae) now contain the human pathogens hRSV
and hMPV, respectively. Serological surveys have in-
dicated that the prevalence of hMPV in the Dutch pop-
ulation is high, because virtually all children tested were
seropositive before the age of 6 years [4]. Recently,
hMPV was also detected in children, adults, elderly in-
dividuals, and immunocompromised individuals with
RTI, in Australia, North America, the United Kingdom,
and Finland [8–13], indicating that it is a common and
ubiquitous human pathogen.
In the present study, all respiratory samples obtained
from patients in the university hospital in Rotterdam,
over a period of 17 months, were tested for the presence
of hMPV RNA by reverse-transcriptase polymerase
chain reaction (RT-PCR). We compared the clinical
symptoms of hMPV-infected patients with those of pa-
tients infected with other respiratory viruses. Our data
indicate that, in an academic hospital setting, the prev-
alence and clinical severity of hMPV infections are
slightly lower than those of hRSV infections. Never-
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theless, we conclude that hMPV is an important cause of RTI,
primarily in infants and immunocompromised individuals,
during the winter months.
SUBJECTS, MATERIALS, AND METHODS
Data collection. Between 28 September 2000 and 16 Feb-
ruary 2002, 645 throat-swab, 844 nasopharyngeal-aspirate, 18
sputum, and 297 bronchoalveolar-lavage samples were obtained
at the different wards of the university hospital in Rotterdam
and were sent to the diagnostic virology laboratory. For 1515
of these samples (573 throat-swab, 661 nasopharyngeal-aspi-
rate, 12 sputum, and 269 bronchoalveolar-lavage samples), suf-
ficient material was available for hMPV testing. Of these sam-
ples, 45% were sent specifically for testing for respiratory
viruses, including influenza A and B viruses, hRSV, human
parainfluenza virus (PIV) types 1–4, adenovirus, and rhino-
virus. Routine virological testing for respiratory pathogens was
performed by use of a combination of direct immunofluores-
cence (DIF) on cells present in the respiratory specimen, virus
isolation in cell cultures, and immunofluorescence (IF). Cell
lines used for virus isolation included human embryonal kidney
cells, tertiary monkey kidney cells, Madine Darby canine kidney
cells, Vero cells, and Hep-2 cells. After diagnosis of enterovirus
infection by virus isolation, IF, and/or DIF, a PCR was per-
formed with rhinovirus-specific primers [14]. Of the throat-
swab samples, 622 were obtained from transplant recipients
and were submitted for testing for herpes simplex virus (HSV)
types 1 and 2, cytomegalovirus, and Epstein-Barr virus and
were used here as controls. Throat-swab samples were collected
in virus transport media [15], and other samples were stored
without virus transport media. All samples were kept at 4C
during processing and subsequently were stored for prolonged
periods at 70C.
Detection of hMPV RNA by RT-PCR. RNA was isolated
from a 40–200-mL sample by use of a High Pure RNA isolation
kit (Roche Diagnostics), according to the manufacturer’s in-
structions. RT-PCRs were performed by use of a 1-tube reaction
with primers L6 (5′ CAT GCC CAC TAT AAA AGG TCA G
3′) and L7 (5′ CAC CCC AGT CTT TCT TGA AA 3′), amplifying
a conserved fragment of 170 nt in the polymerase gene. This
RT-PCR was optimized with respect to enzymes, buffer com-
ponents, and cycling parameters and was found to be 10–100-
fold more sensitive than inoculation of tertiary monkey kidney
cells with titrated virus stocks (data not shown). Moreover, the
assay can detect the genetically diverse hMPV isolates described
elsewhere [4]. The L gene was chosen as a target for RT-PCR
because of nucleotide-sequence conservation, thereby reducing
the chance of missing genetic lineages of hMPV that have not
been detected previously. PCRs were performed in a 50-mL
volume containing 50 mmol/L Tris Cl (pH 8.5), 50 mmol/L
NaCl, 4.5 mmol/L MgCl2, 0.2 mmol/L each primer, 0.6 mmol/L
each dNTP, 20 U of RNAsin, 10 U of avian myeloblastosis virus
RT, and 5 U of Taq DNA polymerase (all enzymes from Pro-
mega). Thermocycling was performed in an MJ PTC-200 ap-
paratus (MJ Research) with the following cycling parameters: 45
min at 42C and 5 min at 95C once; 1 min at 95C, 2 min at
45C, and 3 min at 72C repeated 40 times; 10 min at 72C once;
and storage at 4C. PCR products were analyzed by dot-blot
hybridization, as described elsewhere [15], by use of a biotinyl-
ated oligonucleotide (5′ CTG TTA ATA TCC CAC ACC AGT
GGC ATG C 3′).
Clinical evaluation and statistical analysis. The medical
files of hMPV-infected children were scored by pediatricians,
as described elsewhere [16]. In brief, scoring lists included dem-
ographic data (sex, age, number of children and parents in the
family, gestational age, weight at birth, breast-feeding status,
and underlying disease of the patient or in the family), clinical
symptoms (cough, rhinitis, body temperature, dyspnea, wheez-
ing, feeding difficulties, retractions, respiratory rate, pulse, and
cyanosis), laboratory testing (oxygen saturation, pCO2, he-
moglobin, hematocrit, platelet counts, levels of C-reactive pro-
tein, and chest X-ray results), and intervention and follow-up
(artificial respiration, administration of oxygen, use of bron-
chodilators, and administration of antibiotics and corticoste-
roids). The medical files for 25 hRSV-infected children were
scored for comparison. For each hMPV-infected child, an
hRSV-infected child of the same sex who was hospitalized dur-
ing the same period (2–3 weeks range) and was closest in age
to the hMPV-infected child was selected. Demographic and
clinical variables were calculated for the hMPV and the hRSV
groups, respectively, and were expressed as point estimates,
using percentages for dichotomous variables or means with
95% confidence intervals (CIs) for continuous variables, by use
of SPSS for Windows (version 9.0; SPSS). For each variable,
the difference between both point estimates with 95% CIs
(hMPV vs. hRSV) was calculated by use of the software pro-
gram Confidence Interval Analysis (version 1.0; BMJ Publishing
Group) [17]. If the CI of the difference did not include zero,
the corresponding point estimates were regarded as significantly
different.
RESULTS
Prevalence of hMPV. Fifty-two samples obtained from 46
patients (28 males and 18 females) tested positive for hMPV
by RT-PCR. For 44 of these 46 hMPV-positive patients, the
samples had been obtained specifically because of respiratory
symptoms, including fever, cough, rhinorrhea, dyspnea, tach-
ypnea, rhinitis, bronchitis, bronchiolitis, and pneumonia (see
below). The throat-swab samples obtained from the 2 other
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Figure 1. A, Age distribution of patients infected with human metap-
neumovirus (hMPV) (top) or human respiratory syncytial virus (hRSV) (bot-
tom). B, Age distribution of hMPV-infected (black bars) and hRSV-infected
(white bars) children !2 years old. The proportion of children in each age
group was calculated relative to the no. of children !2 years old.
patients were sent for HSV testing, but these patients may also
have experienced a mild or subclinical RTI.
Of the 46 hMPV-infected patients, 37 were hospitalized in
the wards of the children’s hospital, 4 were hospitalized in the
nursing rooms of the cancer center, and 5 were hospitalized in
other departments of Erasmus Medical Center (including the
departments of neurology, hematology, and internal medicine).
The age distribution of the patients with RTI who tested positive
for hMPV is depicted in figure 1. Most of the hMPV-positive
patients were children !2 years old who did not have illnesses
other than RTI. Of the hMPV-positive patients who were 15
years old, most had other diseases (e.g., cystic fibrosis, leukemia,
and non-Hodgkin lymphoma) or had recently received bone-
marrow or kidney transplants. These latter hMPV infections may,
therefore, have been associated with host immunosuppression.
Although the overall age distribution of hMPV-positive patients
was found to be fairly similar to that of hRSV-positive patients
in this same cohort (figure 1A), hMPV was found significantly
less frequently in children !2 months old than was hRSV. Of the
31 hMPV-positive children !2 years old, only 4 (13%) were !2
months old, whereas 43 (35%) of the 122 hRSV-positive children
!2 years old were also !2 months old (rate difference,22.3%;
95% CI, 36.9% to 7.8%).
We obtained, from 4 hMPV-infected patients, 11 sample that
tested positive for hMPV RNA. Three of these patients were
2-, 11-, and 16-month-old children, and virus was detected in
nasal-aspirate samples obtained from them 6, 3, and 6 days
apart, respectively. The fourth patient was a 36-year-old bone
marrow–transplant recipient who was recovering from vari-
cella-zoster pneumonia and subsequent infection with influ-
enza B virus; 4 of this patient’s respiratory-tract specimens,
obtained during a 19-day period, tested positive for hMPV.
hMPV was detected predominantly in samples obtained dur-
ing the winter months (figure 2). The seasonal distribution of
hMPV-positive samples was found to be largely similar to that
of hRSV-positive samples, with the peak of virus detection in
December and January, in both the 2000–2001 and 2001–2002
winter seasons. hMPV may be slightly less seasonal than hRSV,
since the number of hRSV diagnoses in these 2 seasons was
higher than the number of hMPV diagnoses.
To compare the effect of hMPV to that of other respiratory
viral pathogens more quantitatively, we compared the diag-
nostic outcome for 685 specimens sent to the diagnostic vi-
rology laboratory specifically for respiratory pathogen testing
and for which sufficient material was available to complete all
tests. The routine testing for respiratory pathogens in our di-
agnostic virology laboratory included influenza virus types A
and B, hRSV, PIV types 1–4, rhinovirus, and adenovirus. hRSV
was detected most frequently, in 126 (18%) of 685 samples
obtained from patients with RTI, and hMPV was the second-
most-detected viral pathogen, in 48 (7%) of 685 samples (figure
3). Thus, from patients with RTI, hMPV was isolated more
frequently than PIV (9, 2, 7, and 0 samples were positive for
PIV types 1–4, respectively), adenovirus (8 samples), rhinovirus
(28 samples), and influenza viruses types A and B (11 and 7
samples, respectively). It is important to note that the sensi-
tivities of detection methods for the range of viral pathogens
may be different, making it difficult to compare the contri-
bution of each viral pathogen to the RTI quantitatively. It
should also be noted that the influenza virus epidemics in these
seasons were milder than those in previous years. From 6 of
the hMPV-positive samples, we isolated another respiratory
virus: hRSV was isolated from 3 samples, and rhinovirus, in-
fluenza A virus, or adenovirus each was isolated from 1 sample.
hMPV RNA was detected in only 2 of 622 samples obtained
from patients who did not have RTI, suggesting that subclinical
hMPV infection is rare in hospitalized patients.
Clinical symptoms. We next examined the medical files
of hMPV-infected children. Because the underlying disease for
most hMPV-infected adults could have obscured the hMPV-
related RTI, we limited these analyses to otherwise healthy chil-
dren. Medical files were available for 25 of these children, and
the medical files for 25 selected hRSV-infected children were
used as controls.
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Figure 2. Detection of human metapneumovirus (hMPV) (top) and
human respiratory syncytial virus (hRSV) (bottom), per month, between
September 2000 and March 2002.
Figure 3. Comparison of the frequency of detection of human meta-
pneumovirus (hMPV) with those of other respiratory viral pathogens, in
685 samples obtained from patients with respiratory tract illness. Adeno,
adenovirus; Entero, enterovirus; Flu, influenza virus; PIV, parainfluenza
virus; Rhino, rhinovirus; RSV, respiratory syncytial virus.
Demographic data were similar for the hMPV- and hRSV-
infected groups (table 1). There were slightly more boys than
girls in both groups. Although not statistically significant, the
mean age was slightly higher in the hMPV-infected group than
in the hRSV-infected group. Virtually all the children in both
groups who had siblings were the youngest children in the
family, and the household compositions (numbers of children
and adults) were similar. The pre- and perinatal data for the
2 groups (e.g., gestational age, birth weight, and breast-feeding
status) were also not significantly different. In contrast, history
of asthma was more often associated with hMPV than with
hRSV infection: 16% of the hMPV-infected patients had asthma
and 67% of them had a family member with asthma, whereas
none of the hRSV-infected patients had asthma and only 30%
of them had a family member with asthma.
The clinical symptoms observed for the hMPV-infected chil-
dren included cough (72%), rhinitis (80%), fever (61%), dysp-
nea (28%), wheezing (24%), feeding difficulties (36%), retrac-
tions (60%), hyperventilation (42%), tachycardia (23%), and
cyanosis (8%). Most of these symptoms were observed with
similar frequency in the group of hRSV-infected children. How-
ever, dyspnea, feeding difficulties (primarily, decreased intake
of food), and hypoxemia were reported significantly more fre-
quently in hRSV-infected children than in hMPV-infected chil-
dren. Platelet counts, relative white blood cell counts, and levels
of C-reactive protein were similar for both groups. For 62%
of the children, an X-ray of the lungs revealed atelectasis, hy-
perinflation, and infiltrates as the most common abnormalities,
in both groups of patients.
In agreement with the finding of a high number of hRSV-
infected patients with hypoxemia, oxygen was administered to
significantly more hRSV-infected patients than hMPV-infected
patients (64% vs. 36%). In contrast, hMPV-infected patients
were treated more often with bronchodilators (36% vs. 24%),
antibiotics (60% vs. 12%; statistically significant), and cortico-
steroids (20% vs. 4%) than were hRSV-infected patients (table
1). The mean duration of hospital stay was similar for both
patient groups (6–7 days). It should be noted that, for this latter
analysis, 3 hMPV-infected children were excluded because of
additional morbidity that was presumably unrelated to the hMPV
infection, such as subsequent infection with other pathogens.
DISCUSSION
Since the discovery of hMPV, several studies have provided
important information on hMPV epidemiology, clinical symp-
toms associated with hMPV infection, and the patient groups
that are at risk for hMPV infection [4, 8–13]. From these stud-
ies, it is now becoming increasingly clear that hMPV is an
important human pathogen associated with RTI in young chil-
dren, immunocompromised individuals, elderly individuals,
and, to a lesser extent, other populations. In the present study,
we analyzed the relative contribution of hMPV to RTI, in a
university hospital setting, and compared the clinical signs with
those caused by infection with a related pathogen, hRSV.
In the 2000–2001 and 2001–2002 winter seasons in The
Netherlands, hMPV and hRSV were both found primarily in
December and January; they were rarely detected in the summer
months. It should be noted that, during these years, hMPV
infections were temporally distributed somewhat more equally
than were hRSV infections. The populations of patients most
affected by the 2 viruses—children, immunocompromised in-
dividuals, and elderly individuals—were also quite similar, as
was the overall age distribution of the infected patients. How-
ever, it is interesting to note that hRSV was detected more
frequently in very young children than was hMPV; 35% of
hRSV-infected children !2 years old were also !2 months old,
compared with only 13% of the hMPV-infected children !2
years old. Whether this observed difference is a true reflection
Table 1. Data from medical files of patients infected with human metapneumovirus (hMPV) and human
respiratory syncytial virus (hRSV).
Characteristic
hMPV hRSV
95% CI
of differenceb
No. of
patients
Point
estimatea
No. of
patients
Point
estimatea
Demographics
Sex, % male 25 64.00% 25 56.00% 19.1 to 35.1
Age, months 25 15.0 (8.3–21.6) 25 11.2 (5.4–16.9) 4.8 to 12.4
Patient with asthma 25 16.00% 25 0.00% 1.6–30.4
Asthma in family 9 66.70% 20 30.00% 0.1 to 73.4
Clinical symptoms and laboratory tests
Cough 25 72.00% 25 76.00% 28.3 to 20.3
Rhinitis 25 80.00% 25 72.00% 15.6 to 31.6
Fever 18 61.10% 23 47.80% 17.1 to 43.7
Dyspnea 25 28.00% 25 76.00% 72.3 to 23.7
Wheezing 25 24.00% 25 32.00% 32.8 to 16.8
Feeding difficulties 25 36.00% 25 76.00% 65.2 to 14.8
Retractions 25 60.00% 25 64.00% 30.9 to 22.9
Hyperventilation 19 42.10% 24 37.50% 24.9 to 34.1
Tachycardia 17 23.50% 23 52.20% 57.3 to 0.1
Cyanosis 25 8.00% 25 20.00% 30.9 to 7.0
Hypoxemia 19 47.40% 22 81.80% 62.1 to 6.8
Hypercapnia 14 42.90% 17 41.20% 33.2 to 36.6
Decreased hemoglobin 22 22.70% 23 13.00% 12.6 to 32.0
Decreased hematocrit 21 33.30% 21 19.00% 12.0 to 40.5
Thrombocytosis 21 9.50% 19 31.60% 46.4 to 2.3
Illness scorec 25 0.38 (0.33–0.44) 25 0.50 (0.44–0.56) 0.20 to 0.03
C-reactive protein 18 35.9 (2.8–69.1) 20 39.2 (15.7–62.7) 41.8 to 35.3
Chest X-ray performed 25 60.00% 25 64.00% 30.9 to 22.9
Atelectasis 15 40.00% 16 18.80% 10.1 to 52.6
Hyperinflation 15 33.30% 16 43.80% 44.5 to 23.6
Infiltrate 15 33.30% 16 31.30% 30.9 to 35.0
Bronchial thickening 15 0.00% 16 12.50% 28.7 to 3.7
Intervention and follow-up
Artificial respiration 25 12.00% 25 8.00% 12.6 to 20.6
Oxygen administration 25 36.00% 25 64.00% 54.6 to 1.4
Bronchodilators 25 36.00% 25 24.00% 13.2 to 37.2
Antibiotics 25 60.00% 25 12.00% 25.0–71.0
Corticosteroids 25 20.00% 25 4.00% 1.5 to 33.5
Time in hospital, daysd 15 6.6 (4.6–8.6) 19 6.2 (4.6–7.7) 1.9 to 2.8
NOTE. The groups of hMPV- and hRSV-infected children both included 25 patients, but, because some of the files were
not completed, the no. of patients used for comparison may be lower. The following dichotomous variables were calculated
from continuous variables by use of reference thresholds derived from healthy children: fever (body temperature 38.5C),
hyperventilation (respiratory rate 160 or 140 breaths/min for children !1 or 11 year old, respectively), tachycardia (pulse 1175,
1177, 1163, and 1143 for children 0–3, 3–6, 6–12 and 112 months old, respectively), hypoxemia (oxygen saturation !95%),
hypercapnia (pCO2 15.6 kPa), decreased hemoglobin (!8.1 or !6.6 mmol/L for children !1 or 11 month old, respectively),decreased
hematocrit (!0.42 or !0.33 L/L for children !1 or 11 month old, respectively), and thrombocytosis (1 or 19 939010 47310
platelets/L for children !1 or 11 month old, respectively). CI, confidence interval.
a Point estimates are given as percentages, for dichotomous variables, or as mean (95% CI), for continuous variables.
b If the 95% CI did not include 0, the corresponding point estimates were considered to be statistically significant and appear
in bold type.
c Each of the 15 clinical symptoms above was scored (1 and 0 for presence and absence, respectively), and the sum was
divided by the no. of recorded symptoms. Thus, the illness score could range from 0.00 (no symptoms present) to 1.00 (all
symptoms present).
d Three cases of hMPV infection were excluded from this comparison because of additional morbidity unrelated to the hMPV
infection.
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of the differences in biological properties of the respective vi-
ruses requires further confirmation. During the 2 winter sea-
sons under study, the 2 genetic lineages of hMPV that were
identified previously [4] were cocirculating in The Netherlands
(data not shown), as has been described recently for other
countries [9, 11, 13]. Differences in the pathogenicity of viruses
belonging to the hRSV subgroups A and B have been described
by some research teams but not by others [18–22]. Unfortu-
nately, at present, our data set is too limited to compare the
relative prevalence and pathogenicity of the distinct lineages of
hMPV in a similar fashion.
Comparison of the medical files of hMPV-infected children
with those of hRSV-infected children revealed that the clinical
symptoms associated with these viruses were quite similar.
Dyspnea, feeding difficulties, and hypoxemia were recorded
more frequently in hRSV-infected children than in hMPV-
infected children, but all other recorded symptoms were found
at the same frequency in both groups. For each of the children,
in both groups, we calculated an illness score, defined as the
number of clinical symptoms the children had, divided by the
total number of symptoms that were recorded for each child
(table 1). This analysis revealed that the hMPV-infected chil-
dren had, on average, 38% of the recorded symptoms, whereas
hRSV-infected children had 50% of the symptoms (statistically
significant), suggesting that hRSV may be slightly more path-
ogenic than hMPV. The higher proportion of children !2
months old in the hRSV group did not have a serious effect
on this observation; reanalysis of the data, excluding children
!2 months old, still resulted in a statistically significant differ-
ence for the illness scores.
It is important to note that subclinical hMPV infections
appear to be rare; we detected hMPV RNA in only 2 of 622
samples obtained from patients who did not have RTI. This
finding, as well as the observation that hMPV may cause mild
RTI in experimentally infected macaques [4], is indicative of
hMPV being a causative agent of RTI. In agreement with these
observations, we did not detect any other pathogens in the
majority of patients with hMPV-related RTI. Three hMPV-
infected patients were also positive for hRSV, and 3 were pos-
itive for either influenza A virus, adenovirus, or rhinovirus. On
the basis of the similar seasonal distribution of hMPV and hRSV
infections (figure 2), dual infection with these 2 viruses is not
unlikely.
The statistical significance of the difference between the pro-
portion of children with asthma in the hMPV group and that
of children with asthma in the hRSV group requires confir-
mation in larger scale studies in the future. Numerous studies
have provided evidence for a link between hRSV infection in
early childhood and subsequent manifestations of asthma [23,
24], although this issue is still being studied [25]. The link
between hMPV infection and asthma appears to be different
from that suggested for hRSV infection. It will be of interest
to further elucidate the underlying mechanisms for the possible
association between asthma and either hRSV or hMPV infec-
tion, in future studies.
It was not surprising that antibiotics and corticosteroids were
administered to hMPV-infected children more often than to
hRSV-infected children. Because hRSV diagnostics were per-
formed in real time, physicians were able to choose not to give
antibiotics and corticosteroids after a positive hRSV diagnosis.
However, because, at the time of hospitalization, no etiological
agent had been identified in children with RTI associated with
hMPV infection, physicians continued treatment with antibi-
otics and corticosteroids, to control potentially unidentified
bacterial infections. This indicates that the inclusion of hMPV
in diagnostic testing of patients with RTI may reduce unnec-
essary use of antibiotics and corticosteroids. Moreover, hMPV
diagnostic testing may reduce virus transmission between chil-
dren in hospital wards, through isolation or alternative mea-
sures currently used to limit the spread of hRSV. For a virus
that is not easily detected by virus isolation in the laboratory,
it will be of great importance that rapid, sensitive, and repro-
ducible diagnostic tests be developed. Our RT-PCR procedure,
which is based on the amplification of a conserved sequence
in the polymerase gene, proved to be more sensitive than virus
isolation and can detect genetically distinct hMPV strains.
However, RT-PCRs based on the N gene may take advantage
of the transcriptional gradient used by paramyxoviruses and,
therefore, may be even more sensitive. In addition, monoclonal
antibodies recognizing conserved hMPV epitopes will be useful
for rapid virus diagnostics by use of IF or DIF techniques
currently used for diagnosing infections with other virus path-
ogens, including hRSV. It will be important to conduct a wide
range of prospective and retrospective studies to obtain a better
estimate of the incidence, prevalence, and clinical effect of
hMPV in different populations, the full spectrum of hMPV
diseases, and risk factors that may be associated with severe
hMPV disease.
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